ClinicalTrials.gg

Program

SHR-2017

A development code. Also written as “SHR-2017 injection”.

In Jiangsu HengRui Medicine's pipeline, RANKL/ NGF. Its studies are mostly in Neoplasm Metastasis · Osteoporosis, led by Jiangsu HengRui Medicine.

Furthest: phase 1, since Jun 26, 20232 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine21 open or runningphase 1since Jun 26, 2023Jun 26, 2023none ahead
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-2017, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 26, 2023First study: phase 1 study in OsteoporosisFirst studyNCT05930704 · 45 planned · China
  2. Apr 18, 2024Phase 1 study in Patients With Bone MetastasesNCT06380881 · 25 enrolled · China

TargetBeta

“RANKL/ NGF”the company's pipeline, read by Claude · source

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06380881Patients With Bone Metastases · China1CompletedAug 6, 202525
NCT05930704Osteoporosis · China1RecruitingApr 12, 202545

How it is read

Names in the registry

  • “SHR-2017”, 1 entry
  • “SHR-2017 injection”, 1 entry

Codes read as this program: SHR2017.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.